Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Sansert: Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Sansert - General Information

An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Sansert is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome. [PubChem]

 

Pharmacology of Sansert

Sansert has been shown, in vitro and in vivo, to inhibit or block the effects of serotonin, a substance which may be involved in the mechanism of vascular headaches. Serotonin has been variously described as a central neurohumoral agent or chemical mediator, as a "headache substance" acting directly or indirectly to lower pain threshold, as an intrinsic "motor hormone" of the gastrointestinal tract, and as a "hormone" involved in connective tissue reparative processes.

 

Sansert for patients

 

Sansert Interactions

Methysergide may reverse the analgesic activity of narcotic analgesics. Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.

 

Sansert Contraindications

Hypersensitivity to the drug or to tartrazine (FD&C Yellow #5) or any other components of the formulation, pregnancy, lactation, peripheral vascular disease, severe arteriosclerosis, severe hypertension, coronary artery disease, phlebitis or cellulitis of the lower limbs, pulmonary disease, collagen diseases or fibrotic processes, impaired liver or renal function, valvular heart disease, debilitated states and serious infections.

 

Additional information about Sansert

Sansert Indication

For the treatment of vascular headache

Mechanism Of Action
Sansert is serotonin antagonists acts on central nervous system (CNS), which directly stimulates the smooth muscle leading to vasoconstriction. Some alpha-adrenergic blocking activity has been reported. Suggestions have been made by investigators as to the mechanism whereby Sansert produces its clinical effects, but this has not been finally established, although it may be related to the antiserotonin effect.
Drug Interactions
Acebutolol Ischemia with risk of gangrene
Generic Name
Methysergide
Synonyms
Methyllysergic acid butanolamide; Methysergid; Methysergidum [INN-Latin]; Metisergide [DCIT]; Metisergido [INN-Spanish]; N-(1-(Hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamide; N-(alpha-(Hydroxymethyl)propyl)-1-methyl-dextro-lysergamide
Drug Category
Vasoconstrictor Agents; Serotonin Antagonists; Sympatholytics
Drug Type
Small Molecule; Approved
Other Brand Names containing Methysergide
Deseril; Desernil; Desernyl; Deseryl; Sansert;
Absorption
Rapid
Toxicity (Overdose)
Few cases of acute methysergide intoxication have been reported. The possible symptom complex is therefore not fully known. The following symptoms are based on these few case reports. Euphoria, hyperactivity, tachycardia, dilated pupils, and dizziness have been reported in a child with a dose of 20-24 mg of methysergide. In adults, peripheral vasospasm, with diminished or absent pulses, coldness, mottling and cyanosis, has been observed at a dose of 200 mg. Ischemic tissue damage has not been reported in acute overdosage with methysergide.
Biotransformation
Hepatic
Dosage Forms of Sansert
Tablet Oral
Chemical Formula
C21H27N3O2
Organisms Affected
Humans and other mammals